On April 23, 2026, BPC-157 officially came off the FDA’s Category 2 restricted list. If you’ve been following the peptide space for the last three years, that sounds like the green light you’ve been waiting for. But here’s the part almost every headline got wrong: removal from Category 2 is not the same thing as being legal to compound, and it is definitely not the same as FDA approval. Those are three completely different regulatory statuses, and confusing them will cost you money or safety or both.
⚡ Key Takeaway
BPC-157 is off Category 2 as of April 2026, but it still cannot be legally compounded until the PCAC votes favorably on July 23 and the FDA publishes a final rule — realistically late 2026 or Q1 2027.
What Category 2 Actually Meant
In late 2023, the FDA placed 19 peptides on its Category 2 list, a designation that effectively told compounding pharmacies: do not compound this substance. Category 2 meant the FDA had identified what it considered significant safety concerns or insufficient data to support compounding. For BPC-157, that was a gut punch to the recovery community. The peptide had been widely used under physician supervision through 503A pharmacies, and overnight, that access vanished.
The practical effect was immediate. Compounding pharmacies pulled BPC-157 from their catalogs. Clinicians who had been prescribing it for gut repair, tendon recovery, and post-surgical healing had to find alternatives or refer patients to the research-grade market. The demand didn’t disappear — it just moved underground.
What the April 2026 Removal Means
HHS Secretary Kennedy confirmed on April 15, 2026 that 12 peptides would be removed from Category 2, with the effective date set for April 23. BPC-157 was on that list alongside TB-500, MOTS-c, GHK-Cu (injectable), Melanotan II, Semax, and PEG-MGF, among others.
Here is what that removal actually does: it lifts the “do not compound” flag. That’s it. BPC-157 moves back into regulatory limbo — no longer explicitly restricted, but not yet explicitly approved for compounding either. A 503A pharmacy cannot legally add it back to their catalog just because Category 2 was lifted. They need the peptide to appear on the 503A bulks list, and that requires a favorable vote from the Pharmacy Compounding Advisory Committee.
The July 23 PCAC Vote Is the Real Gate
The PCAC meets July 23–24, 2026 at the FDA’s White Oak Campus. BPC-157 is on the Day 1 agenda alongside KPV, TB-500, and MOTS-c. The committee will evaluate whether each peptide has sufficient evidence and safety data to be added to the 503A bulks list.
A favorable PCAC vote is advisory — the FDA is not legally bound by it, though the agency follows committee recommendations in the vast majority of cases. After a favorable vote, the FDA still has to publish a final rule, which typically takes several months. Realistic timeline for BPC-157 returning to pharmacy shelves: late 2026 to Q1 2027, assuming a favorable vote.
What This Means for Your Recovery Protocol
If you’re using research-grade BPC-157 for recovery right now, the Category 2 removal changes nothing about your current sourcing. Research-grade peptides were never on Category 2 to begin with — that list only governed compounding pharmacies. The removal matters for the future: if the PCAC votes yes on July 23, you’ll eventually have a legal, prescribed, pharmacy-compounded option with better quality controls than the research market can guarantee.
In the meantime, if you’re sourcing research-grade BPC-157, the same rules apply. Demand a Certificate of Analysis showing purity at or above 98%. Verify the COA comes from an independent third-party lab, not the vendor’s in-house testing. And understand that “research purposes only” is the legal framing — these products are not approved for human use regardless of Category 2 status.
The Three Statuses, Untangled
Category 2 (removed): The FDA’s “do not compound” flag. Removed April 2026. This was a restriction, not an approval.
503A Bulks List (pending): The list of substances that compounding pharmacies can legally use to prepare patient-specific prescriptions. BPC-157 is being reviewed for this list at the July 23 PCAC meeting.
FDA Approval (does not exist): Full drug approval requires Phase 1–3 clinical trials, an NDA filing, and FDA review. No company has filed an NDA for BPC-157. This is not on any foreseeable timeline.
Getting these confused is how people end up either overpaying for “legal” products that aren’t actually more legal, or underestimating the risk of products that have zero regulatory oversight. Know where BPC-157 actually stands, and plan accordingly.